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The circulatory system is one of the ﬁrst systems that develops during embryogenesis.
Angiogenesis describes the formation of blood vessels as a part of the circulatory system
and is essential for organ growth in embryogenesis as well as repair in adulthood. A
dysregulation of vessel growth contributes to the pathogenesis of many disorders. Thus,
an imbalance between pro- and antiangiogenic factors could be observed in infantile
hemangioma (IH). IH is the most common benign tumor during infancy, which appears
during the ﬁrst month of life. These vascular tumors are characterized by rapid proliferation
and subsequently slower involution. Most IHs regress spontaneously, but in some
cases they cause disﬁgurement and systemic complications, which requires immediate
treatment. Recently, a therapeutic effect of propranolol on IH has been demonstrated.
Hence, this non-selective β-blocker became the ﬁrst-line therapy for IH. Over the last years,
our understanding of the underlying mechanisms of IH has been improved and possible
mechanisms of action of propranolol in IH have postulated. Previous studies revealed that
gap junction proteins, the connexins (Cx), might also play a role in the pathogenesis of
IH. Therefore, affecting gap junctional intercellular communication is suggested as a novel
therapeutic target of propranolol in IH. In this review we summarize the current knowledge
of the molecular processes, leading to IH and provide new insights of how Cxs might be
involved in the development of these vascular tumors.
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The circulatory system is one of the ﬁrst systems that develops
during embryogenesis. For the development of other organs a
sufﬁcient supply with oxygen and nutrients is required, which is
mediated through blood vessels as a part of the circulatory system.
The formation of blood vessels plays a major role in growth and
development of organs in the embryo aswell as wound healing and
organ regeneration in adulthood (Carmeliet, 2005). The estab-
lishment of the circulatory system is a two step process. During
vasculogenesis endothelial precursor cells form a primitive vascu-
lar network. This primitive network expands during angiogenesis
by sprouting and growth of pre-existing vessels, thereby forming
new blood vessels. As a result a highly organized vascular network
is formed, consisting of arteries, veins, and capillaries (Eichmann
et al., 2005). In view of the crucial role of angiogenesis in life, it
is not surprising that this process underlies accurate regulatory
mechanisms, requiring a ﬁnely tuned balance between pro- and
antiangiogenic factors (Conway et al., 2001). An imbalanceof these
mediators and thus, a dysregulation of vessel growth are associated
with the pathogenesis of many disorders, especially tumorigenesis
(Carmeliet and Jain, 2000; Carmeliet, 2003). Folkman (1971) pro-
posed for the ﬁrst time the critical role of angiogenesis in tumor
growth and metastasis. While angiogenesis is essential for the for-
mation of new blood vessels in the embryogenesis, most blood
vessels remain quiescent in adulthood. However, in tumorigenesis
there is a shift in favor of proangiogenic factors, which induce
angiogenesis and as a result the formation of new blood ves-
sels. The underlying mechanisms of how angiogenesis promotes
tumor progression and metastasis are not completely understood.
In the past, more and more research focused on the inﬂuence of
gap junctional coupling during tumorigenesis (Naus et al., 1991;
Jamieson et al., 1998; Yamasaki et al., 1999; Saunders et al., 2001;
Zhang et al., 2003).
Intercellular communication within the vasculature is essential
for vessel formation and themaintenance of normal vascular func-
tion. In the vascular system a direct cell-to-cell communication
is ensured by transmembrane channels, known as gap junctions.
Gap junction channels, linking the cytoplasm of neighboring cells,
allow an electrical coupling as well as a metabolic coupling via
exchange of metabolites, ions, and other messenger molecules up
to a molecular mass of 1 kDa. A gap junction channel consists
of two hemichannels (connexons), whereby each neighboring cell
contributes one hemichannel. Each connexon is composed of six
gap junction proteins, called connexins (Cx) (Dhein et al., 2002).
In mammals, at least 21 connexin isoforms have been character-
ized (Söhl and Willecke, 2004). All Cxs are comprised of four
transmembrane-spanning domains, two extracellular domains,
and a cytoplasmatic amino- and carboxy-terminal region. In the
vascular wall four Cxs have been found: Cx37, Cx40, Cx43, and
Cx45 (Hill et al., 2001; Isakson et al., 2006, 2008). In most cases,
Cx45 is expressed only by smooth muscle cells (Krüger et al., 2000;
Li and Simard, 2001; Rummery et al., 2002). In contrast, Cx37,
Cx40, and Cx43 have been detected in both, smooth muscle
and endothelial cells, while Cx37 and Cx40 are predominantly
expressed by endothelial cells and Cx43 is the major connexin iso-
form in smooth muscle cells (Little et al., 1995; Gabriels and Paul,
1998; van Kempen and Jongsma, 1999; Severs et al., 2001; Hae-
ﬂiger et al., 2004). As Cxs are expressed by endothelial cells as well
as smooth muscle cells heterocellular coupling may occur between
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endothelial cells and smooth muscle cells (myoendothelial junc-
tions). In addition, homocellular coupling between endothelial
cells or smooth muscle cells, respectively, does also occur (De Wit,
2004). There is increasing evidence, suggesting a role of vascu-
lar gap junctions in the conduction of vasomotor response, the
regulation of vascular cell proliferation and migration as well as
vascular cell growth, differentiation, and development (Coutinho
et al., 2003; Liao et al., 2007; Chadjichristos et al., 2008). However,
numerous diseases with vascular abnormalities exhibit an alter-
ation in expression and/or distribution of these Cxs (Laird, 2006;
Brisset et al., 2009; Figueroa and Duling, 2009; Johnstone et al.,
2009). Previous in vitro and in vivo studies indicated an inﬂu-
ence of gap junctions in tumorigenesis, usually demonstrating a
decrease in connexin expression in several neoplastic cells (Czyz,
2008). In addition to vascular abnormalities, mutations in a num-
ber of genes, encoding different Cxs, are associated with various
further disorders (Kar et al., 2012). For example, mutations in the
Cx26 gene (GJB2) cause genetic deafness (Martínez et al., 2009).
Moreover, mutations in the Cx32 gene (GJB1) are involved in
the pathogenesis of X-linked Charcot–Marie–Tooth neuropathy
(Scherer and Kleopa, 2012), while mutations in the gene encoding
Cx43 (GJA1) result in oculodentodigital dysplasia (Paznekas et al.,
2009). Cxs are also known to play an important role in the heart
and previous studies showed several cardiacmalformations caused
by mutations in the cardiac Cx43 and Cx40 gene (GJA1 and GJA5,
respectively) (Delmar and Makita, 2012).
Vascular anomalies are classiﬁed into two categories based
on their clinico-pathophysiologic behavior and endothelial cell
characteristics: vascular malformations and hemangiomas (Mul-
liken and Glowacki, 1982). While vascular malformations describe
structural abnormalities in vessels with normal endothelial
turnover, hemangiomas represent vascular tumors, arising as a
result of rapid growth of endothelial cells (Bruckner and Frieden,
2003). The most common benign vascular tumor during infancy
is the infantile hemangioma (IH).
In this review we summarize the current knowledge of the
pathogenesis of IHs and suggest a role of Cxs in the development
of these vascular tumors.
Most hemangiomas are not present at birth, but appear dur-
ing the ﬁrst month of life with an incidence of 5–10% of all
infants, and up to 30% of premature babies, especially those
with a birth weight less than 1500 g (Drolet et al., 1999, 2008;
Greenberger and Bischoff, 2011). Additionally, there is a higher
risk in female than in male infants and it is often seen in Cau-
casian children (Hemangioma Investigator Group et al., 2007).
There are several types of hemangioma. The capillary heman-
gioma is the most common form of hemangioma, characterized
by a closely packed aggregation of small capillaries, separated
by thin, connective tissue (Mentzel et al., 1994). The capillaries
are normal in size and diameter, but high in number. Another
type of hemangioma is the cavernous hemangioma, compos-
ing of enlarged, dilated blood vessels with blood-ﬁlled cavities
between them. A compound hemangioma exists when there is a
mix of the capillary and cavernous form. IHs may occur through-
out the body, including skin, muscle, bone, and internal organs.
Mostly, they are found on the skin of the head and neck area
(60%). They can also emerge anywhere else on the skin surface
(superﬁcial hemangiomas) like the trunk (25%), limbs (15%) as
well as under the skin (deep hemangiomas), and rarely in organs
like liver, intestine, lung, or brain (Finn et al., 1983). At ﬁrst,
IHs usually appear as small scratch or bruise red bump, which
is why they are also called “strawberry marks”. Depending on the
depth of tissue involvement, the hemangiomas display a bright
red (outer layers of the skin), crimson, purple, bluish, or normal
skin (deep under the skin surface) color. There also exist mixed
hemangiomas, combining clinical features of superﬁcial and deep
hemangiomas (Chang et al., 2008). The size of IHs may also vary,
ranging from a few millimeters to several centimeters in diame-
ter (Drolet et al., 1999). In addition to size there are differences
in the shape of hemangiomas. Most tumors are circumscribed
and exhibit a round or oval shape, but in some cases they may
follow the shape of the affected region. Although, the majority
of IHs are solitary and localized, some hemangiomas may be
diffuse and segmental, covering a broad range of the cutaneous
surface. Hemangiomas, which cannot clearly be classiﬁed as local-
ized or segmental hemangiomas, often referred as intermediate
hemangiomas (Chiller et al., 2002). The IH displays a charac-
teristic life cycle, consisting of an early proliferation phase and
subsequently involution. A few weeks from birth the tumor starts
to grow rapidly. The duration of the proliferation phase varies
betweendifferent hemangioma subtypes,while superﬁcial heman-
giomas grow earlier in infancy and faster than deep hemangiomas.
However, most growth occurs during the ﬁrst 4–6 month of life
(Hochman et al., 2011). After the proliferation phase, which may
last up to 12 month, the tumor undergoes involution and regres-
sion. This can take as long as 5–10 years (Phung et al., 2005). In this
period the involved skin is blanching and the tumor is shrinking
and softening. In 90% of cases IHs regress spontaneously over the
years andno speciﬁc treatment is required (Margileth andMuseles,
1965; Neri et al., 2012). However, hemangiomas may cause disﬁg-
urement due to scar tissue or atrophic, wrinkled, telangiectatic
skin (Wirth and Lowitt, 1998). In some cases, IHs lead to seri-
ous complications, affecting breathing, vision, eating, or hearing,
some become life-threatening and require immediate treatment.
The management of hemangiomas is non-uniform due to their
heterogeneity and depends on several factors like the location
and size of the tumor, the depth of the affected region, the age
of the patient as well as the occurring complications (Maguiness
and Frieden, 2012). Therefore, the treatment of IHs almost fol-
lows on a case-by-case basis. Besides surgical management like
excision of the hemangioma or laser treatment, children often
received a medical therapy (Adams, 2001). Since 1960s corti-
costeroids have been the standard treatment for IH (Cohen and
Wang, 1972). Some infants with life-threatening hemangiomas
failed to respond to corticosteroids. In that case the administra-
tion of interferon-alpha seemed to be successful in treating of
hemangiomas (Ricketts et al., 1994; Chang et al., 1997; Tamayo
et al., 1997; Azzopardi and Wright, 2012). Both, corticosteroid and
interferon-alpha management are associated with a number of
side effects and therefore, the interest in alternate therapies has
increased recently (Barlow et al., 1998; Boon et al., 1999). In the
last years, advances in the treatment of IHs have occurred. As part
of this, a new therapeutic strategy has been added, using propra-
nolol. The therapeutic effect of propranolol was ﬁrst described by
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Léauté-Labrèze et al. (2008). They treated a child, suffering from
a capillary hemangioma, with steroids. Nevertheless, the heman-
gioma still grew and simultaneously an obstructive hypertrophic
myocardiopathy developed. Therefore, they administered propra-
nolol and observed an involution of the hemangioma. Numerous
other studies followed, conﬁrming this inhibitory effect of propra-
nolol on the growth of hemangiomas and thus, this non-selective
β-blocker became the ﬁrst-line therapy for IH (Holmes et al., 2011;
Starkey and Shahidullah, 2011). Until today, the effect of propra-
nolol on IH is not completely understood, but with improving
knowledge of the pathogenesis of IH several possible mechanisms
of action of the β-blocker arised (Storch and Hoeger, 2010). It is
believed that propranolol leads to (1) suppression of angiogen-
esis (2) vasoconstriction of the capillaries, and (3) induction of
apoptosis.
Propranolol is a non-selective β-blocker, inhibiting β1- and
β2-adrenoceptors, and has no partial agonistic effect. In the vas-
culature β2-adrenoceptor is the most abundant β-adrenoceptor,
which is expressed by a number of cell types, including endothe-
lial cells (Guimarães and Moura, 2001; Iaccarino et al., 2005).
β-adrenoceptors are a class of Gs-protein-coupled receptors. Bind-
ing of catecholamines on the receptors results in stimulation of
the sympathetic nervous system, which plays a major role in reg-
ulation of the vascular system. Once the β-adrenoceptors are
activated by catecholamines, a series of signaling pathways are
initiated. This includes the stimulation of the adenylyl cyclase,
which converts adenosine triphosphate (ATP) into cyclic adeno-
sine monophosphate (cAMP). The second messenger cAMP in
turn activates the cAMP-dependent protein kinaseA (PKA),which
phosphorylates numerous intracellular target proteins, involved in
the control of cell proliferation, differentiation, and migration. A
recent study revealed the important role of β-adrenoceptor stim-
ulation in endothelial cells as a major contributor to the initiation
of IH (Mayer et al., 2012). During the characteristic proliferat-
ing phase the hemangioma is composed of a highly packed mass
of rapidly dividing endothelial cells with increased mitotic rates.
Furthermore, pericytes around endothelial cells, and several cell
types like mast cells, and myeloid cells in the interstitium of
the tumor have been identiﬁed. At the involuted phase tumor
growth has stopped and an increase in the number of mast cells
has been observed. On cellular level these two phases can be
separated by speciﬁc markers. In the proliferating hemangioma
there is an increase in the expression of proangiogenic factors
like vascular endothelial growth factor (VEGF) as well as basic
ﬁbroblast growth factor (bFGF), platelet-derived growth factor
(PDGF), type IV collagenase, insulin-like growth factor 2 (IGF-2),
proliferating cell nuclear antigen (PCNA), the integrins α5β3 as
well as α5β1, hypoxia-inducible factor (HIF)-1α, and the matrix
metalloproteinases (MMP)-2 and MMP-9 (Takahashi et al., 1994;
Chang et al., 1999; Ritter et al., 2002; Kleinman et al., 2007; Zhong
et al., 2009). In contrast, the involution phase is characterized by
a reduced expression of VEGF, bFGF, and IGF-2 as well as an
increased expression of the tissue inhibitor of metalloproteinases
(TIMP)-1 (Takahashi et al., 1994; Chang et al., 1999; Przewratil
et al., 2009, 2010; Zhong et al., 2009). Furthermore, there is an
increase in apoptosis, inducing the regression of hemangiomas
(Razon et al., 1998).
Vascular endothelial growth factor is a major regulator of
vasculogenesis and angiogenesis and was ﬁrst described as a vas-
cular permeability factor released by tumor cells (Senger et al.,
1983). With regard to IH, VEGF seems to play a key role
in the pathogenesis of this vascular tumor. VEGF accelerates
tumor growth via different mechanisms, comprising stimulation
of proliferation as well as migration, increased vascular per-
meability, and inhibition of apoptosis (Harris et al., 2002). It
is described that catecholamine-mediated β-adrenoceptor stim-
ulation induces a release and enhanced expression of VEGF
in numerous cell types like cancerous cells (Greenberger and
Bischoff, 2011; Ji et al., 2013). Furthermore, it has been shown
that this is under the control of the cAMP/PKA pathway, acti-
vating Src tyrosine kinases and consequently, the extracellular
signal-regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) signaling cascade, which in fact results in an enhanced
VEGF expression (Eliceiri et al., 1999; Pagès et al., 2000). VEGF
exerts its effect, especially via a paracrine pathway, by binding
to its tyrosine kinase receptor, mostly expressed on endothe-
lial cells. There are several lines of evidence, suggesting a
predominant role of the binding of VEGF-A to VEGFR-2 to
stimulate angiogenesis (Kieran et al., 2012). The ligand–receptor-
interaction again triggers a cascade of signals, including the
ERK/MAPK signaling pathway, which results in the phospho-
rylation of nuclear transcriptional factors and induction of
the expression of several genes, responsible for the prolifera-
tion of vascular endothelial cells (D’Angelo et al., 1997; Storch
and Hoeger, 2010). Therefore, the proangiogenic phenotype
is sustained. In a similar fashion, the expression of bFGF
is modulated by β-adrenoceptor. Thus, a blockade of the β-
adrenoceptor-mediated up-regulation of VEGF and bFGF and
hence, an inhibition of angiogenesis by propranolol seem to
be important in the management of IH (Ji et al., 2013). Beside
β-adrenoceptor stimulation, VEGF expression is also increased
by hypoxia, a powerful inducer of vasculogenesis and angio-
genesis (Sakurai and Kudo, 2011). Like many other tumors IH
develops a hypoxic microenvironment, which becomes obvi-
ous by increased expression and stabilization of HIF-1α during
the proliferation phase of the tumor. Moreover, previous stud-
ies demonstrated a link between β-adrenoceptors and HIF-1α
in several cancer cells, indicating an up-regulation of HIF-
1α by catecholamine-mediated β-adrenoceptor stimulation also
under normoxic conditions (Chim et al., 2012). Recently, it has
been shown that the Src tyrosine kinases are involved in the
hypoxia-induced VEGF expression by transactivating the epider-
mal growth factor receptor (EGFR) tyrosine kinase, which in
turn stimulates the Akt and ERK1/2 pathways (Hu et al., 2010).
These data suggest a role for propranolol in IH via suppres-
sion of the HIF-1α- mediated VEGF expression. Collectively,
one possible mechanism of action of propranolol on IH might
be the reduction of the expression of proangiogenic factors like
VEGF and consequently, inhibition of angiogenesis. In relation
to its antiangiogenic effect in IH, propranolol could also act
via inhibition of the expression of MMPs, the most prominent
proteinase family associated with tumorigenesis. The involve-
ment of MMPs in IH is supported by the ﬁnding of elevated
concentrations of MMP-2 and MMP-9 in the proliferation phase.
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Furthermore, it is well described that catecholamine-mediated
stimulation of β-adrenoceptors leads to an increased expression
of MMP-2 and MMP-9 (Storch and Hoeger, 2010). Based on
the role of MMP-2 and MMP-9 in the migration of endothe-
lial cells and tubulogenesis, a reduction of the expression of
these proteinases by propranolol also indicates an antiangio-
genic effect of the β-blocker. This is in accordance with the
growth arrest and shrinking of the tumor after treatment with
propranolol.
Another hypothesized effect of propranolol in IH is the induc-
tion of vasoconstriction. In this regard, VEGF again seems to
be crucial. VEGF is able to increase vascular permeability and
mediates vasodilatation, both coupled to the formation of nitric
oxide (NO), and therefore contributes to tumor growth. In their
study Parenti et al. (1998) revealed the intracellular pathway of
the VEGF/NO-induced proliferation of endothelial cells. They
demonstrated an increase in cytosolic calcium [apparently by acti-
vation of phospholipase C γ (PLC γ)] upon VEGF stimulation,
activating the calcium/calmodulin-dependent endothelial nitric
oxide synthase (iNOS), which causes the production and release
of NO.NO in turn stimulates the guanylyl cyclase/cyclic guanosine
monophosphate (cGMP)/protein kinase G (PKG) cascade, result-
ing in vasodilatation of endothelial cells. Furthermore, cGMP
activates the ERK/MAPK signaling pathway, leading to cell pro-
liferation. Catecholamines are also able to mediate vasodilatation
by stimulation of β2-adrenoceptors (Storch and Hoeger, 2010).
Accordingly, another possible mechanism of how propranolol
affects IH is the prevention of relaxation of capillary endothelial
cells, consequently leading to vasoconstriction. The link between
β-adrenoceptors, VEGF expression, and NO formation points out
that there is a complex interaction of multiple signaling cascades,
causing vasodilatation. The vasoconstrictive effect of propranolol
on hemangiomas is emphasized by the blanching and softening of
the tumor after propranolol application.
The third mechanism of action of propranolol in IH repre-
sents the induction of apoptosis. Previous studies demonstrated
a role of β-adrenoceptor signaling in cell survival, implicating
the β-adrenoceptor-induced transactivation of EGFR via the Src
tyrosine kinase as a critical step. This transactivation stimulates a
number of antiapoptotic signaling cascades, including the MAPK
cascade, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
as well as the nuclear factor κB (NFκB) cascade (Zhang et al.,
2009). As a result, cell proliferation is stimulated, expression of
antiapoptotic proteins is induced, and the caspase cascade is inhib-
ited. Hence, propranolol could induce apoptosis by preventing the
β-adrenoceptor-mediated cell survival.
Among the above mentioned mechanisms, the success of pro-
pranolol therapy in IH might also be attributable in affecting
intercellular communication. In the past, it has been described
that a reduction in intercellular communication is associated
with increased susceptibility of cells to neoplastic transformation
(Geletu et al., 2012). As gap junction channels conduct growth-
regulating signals from cell-to-cell, an impaired gap junctional
coupling results in uncontrolled cell growth and therefore, lead-
ing to tumor promotion. Furthermore, studies, investigating the
involvement of gap junction intercellular communication (GJIC)
in carcinogenesis, conﬁrmed a major role of connexin expression
and localization in the control of cell growth (Yamasaki et al.,
1999). Many reports show a down-regulation of connexin expres-
sion in numerous neoplastic cell lines and primary tumors (Czyz,
2008). Interestingly, a previous study revealed a role of Cxs
in the pathogenesis of hemangiomas (Simon and McWhorter,
2002). They found that mice, lacking both Cx37 and Cx40 die
perinatally with abnormalities in the vascular system. These vas-
cular anomalies include hemorrhages in skin, testis, intestine,
stomach, and lung, accompanied by dilated blood vessels and
congestion in the affected tissue. Furthermore, they observed
abnormal vascular channels, coalescing into a cavernous blood
pool. These vascular abnormalities were only detected when both
Cx37 and Cx40 are absent. In contrast, mice lacking either Cx37
or Cx40 are viable and do not exhibit such severe vascular phe-
notypes. Thus, the authors suggested an overlapping function of
both Cxs in the development and maintenance of the vascula-
ture in mouse. In a follow-up study the authors could conﬁrm
the dependency of Cx37 and Cx40 on each other in the vascu-
lar endothelium, demonstrating that speciﬁc ablation of either
endothelial Cx37 or Cx40 results not only in an elimination of
the target connexin, but also in a substantial decrease of the
non-ablated connexin (Simon and McWorther, 2003). More-
over, they revealed a reduced interendothelial dye-transfer in
aorta of mice, lacking Cx37 or Cx40, respectively. The effect
of Cx40 ablation on dye-transfer was more pronounced than
ablation of Cx37 and was age-dependent. Elimination of both
Cxs in embryonic aortas completely abolished dye-transfer in
these mice. Thus, expression of Cx37 and Cx40 could be cru-
cial for effective endothelial coupling by forming heteromeric
gap-junction channels, which in turn are required for normal
development and functional maintenance of the mouse vascular
endothelium. This is in accordance with other reports, indicat-
ing a coexpression of Cx37 and Cx40 in endothelial cells (Yeh
et al., 1998; Ko et al., 1999; Simon and McWhorter, 2002). Other
studies also demonstrated the important role of Cx37 and Cx40
in the vascular system, implicating a decrease in intercellular
communication and consequently, an impairment of angiogen-
esis after knock-down of these Cxs (Gärtner et al., 2012). A lot
of research has been carried out to elucidate the underlying
mechanisms of the regulation of connexin expression, most of
them focused on Cx43. The β-adrenoceptor-mediated signaling
pathway has been identiﬁed as a major modulator of the Cx43
expression. It has been postulated that β-adrenoceptor stimu-
lation leads to a PKA-dependent activation of the three MAPK
p38, c-Jun N-terminal kinase (JNK), and ERK1/2, resulting in
a translocation of transcriptional factors like activator protein 1
(AP1) and cAMP response element-binding protein (CREB) into
the nucleus, which ﬁnally bind to the Cx43 promoter and thus,
inducing connexin expression (Salameh et al., 2009). Furthermore,
β-adrenoceptor stimulation induces elevated concentration of
intracellular calcium, which in turn activates the calcineurin path-
way. The protein phosphatase calcineurin dephosphorylates the
transcriptional factor nuclear factor of activated T cells (NFAT),
which also translocates into the nucleus and induce the expres-
sion of Cx43 (Salameh et al., 2009). Although, less data are
available of the regulation of Cx37 and Cx40, these observa-
tions indicate an involvement of β-adrenoceptor signaling in the
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regulation of their expression. For example, this is supported
by the study of Dupays et al. (2003), detecting multiple bind-
ing sites for AP 1 in the Cx40 gene and hence, suggesting an
important role of this transcription factor also in the expres-
sion of Cx40. In this regard, a further mechanism of action of
propranolol in IH might affect connexin expression. Suprisingly,
a recent study demonstrated an increased Cx43 protein expres-
sion in rat cardiomyocytes after metoprolol application (Salameh
et al., 2010). Since these ﬁndings do not ﬁt into the classical
scheme of action of the β1-selective adrenoceptor blocker, it is
postulated that metoprolol exerts this Cx43-elevating effect via
a β1-adrenoceptor independent mechanism, possibly by inhi-
bition of Cx43 degradation. This so-called ancillary effect of
β-blockers is well known and could also be observed for propra-
nolol. Marano et al. (2002) revealed an antihypertrophic effect of
propranolol, presumably due to its membrane-stabilizing effect
and independently from its β-adrenergic blocking activity. Hence,
propranolol may increase connexin expression independent of
β-adrenoceptor blockade. Beside the connexin expression, GJIC
is regulated by posttranslational modiﬁcations of Cxs, especially
phosphorylation, ensuring a correct assembly and establishment
of a complete functional gap junction channel. The carboxy-
terminal region of Cxs contains consensus sequences, which can
be phosphorylated by several protein kinases. Depending on the
protein kinase, phosphorylating the connexin, and the phospho-
rylated amino residue (serine, threonine, or tyrosine) of the
connexin, an increase or decrease in GJIC may occur (Dhein
et al., 2002). Previous data indicated that Src tyrosine kinase is
able to phosphorylate Cx43 on tyrosine residue (tyr) 247 and
tyr265, resulting in reduced GJIC. In addition, Src initiates mul-
tiple signaling cascades, activating a number of protein kinases,
which in turn phosphorylate Cx43 (Pahujaa et al., 2007). On
the one hand, Src activates the Ras/Raf/MEK/MAPK pathway.
MAPK are serine/threonine-selective protein kinases, which can
also phosphorylateCx43on serine residues andblockGJIC (Warn-
Cramer et al., 1996). On the other hand, Src stimulates PLC,
leading to an increase in cytosolic calcium levels and activation
of the calcium-dependent protein kinase C (PKC). Additionally,
Src may phosphorylates PKC and thus, directly activates this pro-
tein kinase. PKC, a serine/threonine protein kinase, is again able
to phosphorylate Cx43 on serine residues, which mostly corre-
lates with a reduction in GJIC (Pahujaa et al., 2007). As described
above, Src-mediated signaling cascades play a pivotal role in the
pathogenesis of IH via inducing the expression of angiogenic
factors, causing vasodilatation, and inhibiting of apoptosis. Up
to now, the suggested explanations for the therapeutic effect of
propranolol, leading to regression of IH, focused on the pre-
vention of these events. However, it is also conceivable that the
blockade of the Src-mediated pathways by propranolol suppress
connexin phosphorylation, leading to enhanced GJIC. Recently,
a study of Johnstone et al. (2012) revealed a MAPK-mediated
phosphorylation of Cx43 at the speciﬁc serine residues of its
C-terminus, promoting vascular smooth muscle cell (VSMC)
proliferation, independently of GJIC. It has been shown that in
response to PDGF Cx43 become phosphorylated by MAPK, fol-
lowed by an interaction of the phosphorylated Cx43 with the cell
cycle regulator cyclin E and its associated kinase cyclin-dependent
kinase (CDK)-2 at the cell membrane. Subsequently, the com-
plex of phosphorylated Cx43, cyclin E and CDK-2 internalizes
and activates downstream targets of cyclin E and CDK-2, like
retinoblastoma (Rb) protein, which in turn stimulatesVSMC pro-
liferation. They could also observed that this MAPK-mediated
Cx43 phosphorylation is crucial in regulation of neointima for-
mation in vivo. Due to the fact that PDGF is elevated in the
proliferation phase of IH, the PDGF-induced proliferation of
VSMC through mechanisms, involving MAPK-mediated Cx43
phosphorylation and complex formation of phosphorylated Cx43
with cyclin E and CDK-2, could also play an important role
in the pathogenesis of IH. As described above, β-adrenoceptor
stimulation results in activation of MAPK, thereby enhancing
the phosphorylation of Cx43, which could be suppressed by
propranolol (Salameh et al., 2009). Furthermore, Ji et al. (2013)
demonstrated that β-adrenoceptor antagonists interact with cell
cycle regulators, for example phospho-Rb, and thus, inhibit cell
proliferation. Therefore, it could be suggested that propranolol
prevent the β-adrenoceptor-mediated activation of theMAPK cas-
cade and thus, the phosphorylation of Cx43. Hence, no interaction
of Cx43 with cell cycle regulators occur and promotion of cell
proliferation is avoided, which ﬁnally could lead to regression of
the IH.
Until today, the role of Cxs in IH is not fully understood
and further experiments are required to clarify the involvement
of Cxs in the development of IH. As described by Gärtner et al.
(2012) knock-down of Cx37, Cx40, and Cx43, respectively, via
siRNA interference in 3D Matrigel culture of human umbilical
vein endothelial cells (HUVEC) resulted in an impairment of cap-
illary network formation. It would be interesting to determine
the capillary formation in an angiogenesis assay of endothelial
cells of mice, lacking both Cx37 and Cx40, which showed hemor-
rhages in different organs (Simon and McWhorter, 2002). Based
on the ﬁndings of Simon and McWorther (2003) that elimina-
tion of Cx37 and Cx40 lead to a complete loss of endothelial
dye-transfer in embryonic aortas of mice, Patch clamp analysis
could provide further insights into the functionality of gap junc-
tion channels in the aortic wall of these mice by investigation of
the electrical gap junctional coupling. In addition, expression and
activity of key regulators of the connexin expression, for example
Src kinase, MAPK, transcription factors, as well as downstream
targets of Cxs, involved in cell cycle regulation and cell prolif-
eration, should be studied in hemangioma tissue of these mice.
Among animal models, an important starting point to reveal a
role of Cxs in IH might be to determine the expression and local-
ization of these gap junction proteins in biopsies of infants with
IH. In a next step, the above mentioned molecular pathways, pos-
sibly involved in IH, could be examined in human hemangioma
tissue.
In summary, there are some explanations for the therapeutic
effect of propranolol on IH, including the reduction of the expres-
sion of angiogenic factors, stimulation of vasoconstriction, and
triggering of apoptosis. Although, the underlying mechanisms are
not completely understood, there is evidence of a pivotal role of β-
adrenoceptor stimulation, leading to the activation of a number of
signaling pathways. Furthermore, these pathways are also involved
in the regulation of Cxs. In this regard, another mechanism of
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FIGURE 1 | Possible mechanisms of action of propranolol in infantile
hemangiomas (IHs). In the absence of the β-adrenoceptor blocker a
catecholamine-induced stimulation of the β-adrenoceptor activates several
signaling pathways, leading to the pathophysiology of IH. This includes signal
cascades, causing (1) angiogenesis via induction of the expression of
proangiogenic factors like VEGF and MMPs (2) vasodilatation via formation
and release of NO, (3) inhibition of apoptosis, and (4) reduction of GJIC and
stimulation of cell proliferation, respectively, via affecting connexin expression
and phosphorylation. In contrast, propranolol treatment results in inhibition of
angiogenesis, stimulation of vasoconstriction, triggering of apoptosis,
increase of GJIC, and prevention of cell proliferation via blockade of these
β-adrenoceptor-mediated pathways, and thus leading to regression of IHs.
Furthermore, propranolol could affect connexin expression independently
from its β-adrenergic blocking activity (see text for details). Arrows indicate
activation; ↑ indicates up-regulation; ↓ indicates down-regulation; ⊥ indicates
inhibition. cAMP, cyclic adenosine monophosphate; CDK-2, cyclin-dependent
kinase 2; cGMP, cyclic guanosine monophosphate; Cx43, connexin43; EGFR,
epidermal growth factor receptor; eNOS, calcium-independent endothelial
nitric oxide synthase; GJIC, gap junctional intercellular communication;
HIF-1α, hypoxia-inducible factor 1; iNOS, calcium-dependent endothelial nitric
oxide synthase; MAPK, mitogen-activated protein kinases; MMP, matrix
metalloproteinase; NFAT, nuclear factor of activatedT cells; NFκB, nuclear
factor κB; NO, nitric oxide; pCx43, phosphorylated connexin43; PI3K,
phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, protein kinase C;
PKG, protein kinase G; pNFAT, phosphorylated nuclear factor of activatedT
cells; VEGF, vascular endothelial growth factor.
action of propranolol has been postulated via enhancement of
GJIC and inhibition of cell proliferation by affecting connexin
expression and phosphorylation. All these possible mechanisms
of action of propranolol in IH are illustrated in Figure 1.
CONCLUSION
Over the last years, knowledge of the molecular mechanisms of
IH has improved, clarifying that several signaling cascades are
involved in the progression of these vascular tumors and that
there is a cross-talk between them. Since propranolol has been
identiﬁed as a new therapeutic option in treating IH, various stud-
ies focused on the underlying mechanisms of how propranolol
affects hemangiomas. Until today, propranolol has become the
ﬁrst-line therapy in IH and some possible mechanisms of action
of propranolol in IH have been postulated, implicating Cxs as a
novel therapeutic target of propranolol in IH. The challenge for
the future will be to elucidate the cellular and molecular basis
and pathways of IH in greater detail to completely understand
the mechanism of action of propranolol and ﬁnally, to optimize
therapy for infants with IH.
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